VACCIBODY AND NEKTAR THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1/2A STUDY ARM EVALUATING VB10.NEO IN COMBINATION WITH BEMPEGALDESLEUKIN - Vaccibody.com
2456
post-template-default,single,single-post,postid-2456,single-format-standard,bridge-core-2.4.3,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-23.8,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive

VACCIBODY AND NEKTAR THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1/2A STUDY ARM EVALUATING VB10.NEO IN COMBINATION WITH BEMPEGALDESLEUKIN

First patient dosed in VB N-01 study arm with VB10.NEO plus Bempegaldesleukin (NKTR-214)

View press release (PDF)